NDA 212154 · Nippon Shinyaku
Viltepso
Viltolarsen · Intravenous
NovelAccelerated approvalPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Mar 11, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Aug 12, 2020
Approved uses
1
Original approval plus efficacy supplements
Registered trials
4
2 Phase 3, 0 recruiting
FAERS reports
170
54 serious, 7 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 2, 2026.
VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VILTEPSO [see Clinical Studies ( 14 )]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. VILTEPSO is an antisense oligonucleotide indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VILTEPSO. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. ( 1 )
Mechanism: VILTEPSO is designed to bind to exon 53 of dystrophin pre-mRNA resulting in exclusion of this exon during mRNA processing in patients with genetic mutations that are amenable to exon 53 skipping. Exon 53 skipping is intended to allow for production of an internally truncated dystrophin protein in patients with genetic mutations that are amenable to exon 53 skipping.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 12, 2020 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLabelLetterReview
1 products under this application
- VILTEPSO · VILTOLARSEN 250MG/5ML (50MG/ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Viltolarsen" as an intervention, any sponsor and status, largest first.
- Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)Pivotal-lookingCompleted
NS Pharma, Inc.Industry
NCT04060199 · 77 participants · Start Apr 14, 2020 · Primary completion Oct 19, 2023
Drug: Viltolarsen; Placebo · For: Duchenne Muscular Dystrophy
Sites: Sacramento, California; Chicago, Illinois; Brisbane, Australia · 40 sites in all
- Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)Pivotal-lookingActive, not recruiting
NS Pharma, Inc.Industry
NCT04768062 · 74 participants · Start Apr 13, 2021 · Primary completion Oct 2025
Drug: Viltolarsen · For: Duchenne Muscular Dystrophy
Sites: Brisbane, Australia; Westmead, Australia; Québec, Canada · 31 sites in all
NS Pharma, Inc.Industry
NCT04956289 · 20 participants · Start Jul 1, 2021 · Primary completion Jun 20, 2023
Drug: Viltolarsen · For: Duchenne Muscular Dystrophy
Sites: Richmond, Virginia; Beijing, China; Changsha, China · 8 sites in all
- Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502)Active, not recruiting
NS Pharma, Inc.Industry
NCT04687020 · 9 participants · Start Jun 10, 2021 · Primary completion Sep 2032
Drug: Viltolarsen · For: Duchenne Muscular Dystrophy
Sites: Sacramento, California; Chicago, Illinois; Durham, North Carolina · 5 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pyrexia21
- vomiting14
- illness11
- weight increased9
- pneumonia8
- malaise7
- cough6
- covid-196
- product dose omission issue6
- diarrhoea5
- fall5
- influenza5
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 1 |
| 2021 | 13 |
| 2022 | 19 |
| 2023 | 29 |
| 2024 | 41 |
| 2025 | 47 |
| 2026 | 20 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Viltepso (Viltolarsen)
2024 spending
$4.3M
Beneficiaries
n/a
37 claims
Per beneficiary
n/a
$289.93 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $4,348,899 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Safety and efficacy of viltolarsen in ambulatory and nonambulatory males with Duchenne muscular dystrophy.
Harper AD, Topaloglu H, Mercuri E, et al. · Sci Rep 2024 · Clinical Trial, Phase II
- Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial.
Clemens PR, Rao VK, Connolly AM, et al. · JAMA Neurol 2020 · Clinical Trial, Phase II, Multicenter Study
- Absorption, Distribution, Metabolism, and Excretion of US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs.
Migliorati JM, Liu S, Liu A, et al. · Drug Metab Dispos 2022 · Meta-Analysis, Review
- Efficacy and Safety of Viltolarsen in Boys With Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study.
Clemens PR, Rao VK, Connolly AM, et al. · J Neuromuscul Dis 2023 · Clinical Trial, Phase II
- Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy.
Clemens PR, Rao VK, Connolly AM, et al. · J Neuromuscul Dis 2022 · Clinical Trial
- Viltolarsen in Japanese Duchenne muscular dystrophy patients: A phase 1/2 study.
Komaki H, Takeshima Y, Matsumura T, et al. · Ann Clin Transl Neurol 2020 · Clinical Trial, Phase I, Clinical Trial, Phase II
Sponsor: Nippon Shinyaku
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.